A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Key facts

Sponsor

Pulnovo Medical (Wuxi) Co., Ltd.

Principal Investigator

Yaling Han

The General Hospital of Northern Theater Command

Intervention

Pulmonary arterial denervation(procedure)

Enrollment

264 enrolled

Eligibility

18-75 years · All sexes

Timeline

2023 – 2027

Study locations (1)

• General Hospital of Northern Theater Command, Shenyang, Liaoning, China

Collaborators

The General Hospital of Northern Theater Command · The First Affiliated Hospital with Nanjing Medical University · First Hospital of Tsinghua University · Cangzhou Central Hospital · Chinese Academy of Medical Sciences, Fuwai Hospital · Guangdong Provincial People's Hospital · The First Affiliated Hospital of Guangzhou Medical University · First Affiliated Hospital of Harbin Medical University · Tongji Hospital · Second Hospital of Jilin University · China-Japan Union Hospital, Jilin University · Shanxi Cardiovascular Hospital · RenJi Hospital · Shanghai 10th People's Hospital · Beijing Anzhen Hospital · West China Hospital · Sichuan Academy of Medical Sciences · The First Affiliated Hospital of Soochow University · TEDA International Cardiovascular Hospital · Tianjin Medical University General Hospital · Renmin Hospital of Wuhan University · Zhongnan Hospital · First Affiliated Hospital Xi'an Jiaotong University · Xiamen Cardiovascular Hospital, Xiamen University · Zhejiang University · Shengjing Hospital · First Affiliated Hospital of Fujian Medical University · First Affiliated Hospital of Wenzhou Medical University · Gansu Provincial Hospital · Yanan Hospital of Kunming City · First Affiliated Hospital of Chongqing Medical University · Huaihe Hospital of Henan University · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · The First Affiliated Hospital of Nanchang University · Hunan Provincial People's Hospital · Tianjin Medical University Second Hospital · First Affiliated Hospital, Sun Yat-Sen University · The First Hospital of Jilin University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06872112
  A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
  Joseph C. Wu
• RECRUITINGPHASE2NCT06351345
  129 Xenon Imaging in Patients Treated With Sotatercept
  Bastiaan Driehuys
• RECRUITINGPHASE4NCT07140484
  Sotatercept in Pulmonary Arterial Hypertension
  University of Alberta
• RECRUITINGPHASE2NCT07175038
  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
  AllRock Bio, Inc.
• RECRUITINGNCT07013149
  The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
  University of Sao Paulo General Hospital
• RECRUITINGNCT06998329
  PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
  University of Sao Paulo General Hospital
• ENROLLING BY INVITATIONPHASE2NCT06992440
  Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
  Gustavo A Heresi, MD, MS
• RECRUITINGNANCT06968962
  Comparison of Sequential to Initial Combination Therapy in PAH
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Drug- or toxin-induced pulmonary arterial hypertension →